Drug Farm Announces anti-HBV immunomodulator, DF-006 is Accepted as a Late-Breaking Presentation at the 2024 European Association for the Study of the Liver Conference
May 02 2024 - 6:48AM
Business Wire
Drug Farm, a private biotechnology company utilizing genetics
and artificial intelligence technologies to discover and develop
innovative, immune-modulating therapies, today announced that the
chronic hepatitis B patient data from their Phase 1b trial
(ACTRN12621000592842) was accepted as a late breaking poster
presentation at the 2024 European Association for the Study of the
Liver (EASL) conference that will be held in Milan, Italy between
05 June 2024 to 08 June 2024.
Poster #LB46
Title: A phase 1, double-blinded, randomized,
placebo-controlled, multicenter global study evaluating the safety,
tolerability, and antiviral activity of DF-006 in chronic hepatitis
B, virologically-suppressed patients.
Date: 05 June 2024
Time: 8.30 am – 5.00 pm CET
DF-006 is a first-in-class, orally administered ALPK1 agonist
immunomodulator that potently stimulates local, innate immunity in
the liver1. DF-006 has successfully completed single and multiple
ascending dose (MAD) evaluation in healthy volunteers, and MAD
evaluation in virologically suppressed HBeAg negative chronic
hepatitis B (CHB) patients. “There remains no effective cure for
CHB. DF-006 has a novel mechanism of action that is capable of
stimulating the body’s own immune system to help clear the
infection. As an oral drug administered once weekly, DF-006 has the
potential to be the immunomodulator of choice in combination HBV
cure regimens”, said Dr. Ed Gane, Professor of Medicine at the
University of Auckland, New Zealand and Chief Hepatologist,
Transplant Physician, and Deputy Director of the New Zealand Liver
Transplant Unit at Auckland City Hospital.
“DF-006 has demonstrated potent antiviral responses in
preclinical studies, including inhibition of cccDNA and recruitment
of T-cells. The data from this trial study now provides clinical
support for a drug with a novel mechanism of action that could be
used to help cure CHB patients”, said Drug Farm’s Chief Medical
Officer, Dr. Jeysen Yogaratnam.
About Drug Farm.
Drug Farm is a private biotechnology Company developing
innovative treatments targeting innate immunity for hepatitis B,
cancer, and autoimmune diseases. Drug Farm's unique IDInVivo
platform combines breakthrough technologies in genetics and AI to
discover new treatments. IDInVivo technology allows the direct
assessment of gene targets in living animals with intact immune
systems. Using the IDInVivo platform, Drug Farm has identified
novel innate immunity pathways and targets and is now rapidly
advancing multiple first-in-class drug candidates into clinical
development. For more information please visit:
www.drug-farm.com
Reference:
- Xu C, et al. Hepatology. 2023 Jan 1;77(1):275-289. doi:
10.1002/hep.32614. Epub 2022 Sep 17.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502003325/en/
United States: Henri Lichenstein, Ph.D. Chief Executive Officer
Email: hlichens@drug-farm.com China: Tony Xu, Ph.D. Co-founder and
Chief Operating Officer Email: tony.xu@drugfarminc.com